Lung Cancer (Diagnosis) Clinical Trial
Official title:
Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis
NCT number | NCT03830619 |
Other study ID # | WuhanUH2018 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2017 |
Est. completion date | July 31, 2021 |
Verified date | November 2021 |
Source | Wuhan Union Hospital, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study is to investigate the sensitivity and specificity of serum exosome noncoding RNA as a biomarker for the diagnosis of lung cancer
Status | Completed |
Enrollment | 1000 |
Est. completion date | July 31, 2021 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Subjects are willing to sign the informed consent form; - Normal subjects have no evidence of any disease; - Lung cancer patients are 18 to 75 years old, diagnosed as lung cancer by histopathology or cytopathology Exclusion Criteria: - People are unwilling to sign the informed consent form; - Patients with heart disease, rheumatic disease, allergic disease, COPD, pulmonary fibrosis, diabetes, thyroid disease, liver, kidney, brain disease and hematopoietic system disease; - Pregnant or lactating women; - Patients did not cooperate or participate in other clinical trials |
Country | Name | City | State |
---|---|---|---|
China | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Wuhan Union Hospital, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The expression levels of serum exosome long non-coding RNA | the first day subjects are enrolled the outcome will be assessed;up to three years after the completion of the study | ||
Primary | the expression levels of tumor biomarkers such as CEA, NSE, SCC, CYFR2A-1 | the first day subjects are enrolled the outcome will be assessed;up to three years after the completion of the study | ||
Primary | the CT scans of the lung for the patients | the first day subjects are enrolled the outcome will be assessed;up to three years after the completion of the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03479099 -
Liquid Biopsy in Lung Cancer
|
||
Active, not recruiting |
NCT05110131 -
Evaluation of the Synergistic Impact of Needle and Forceps Biopsy With Electromagnetic Navigation Bronchoscopy
|
N/A | |
Completed |
NCT03633006 -
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
|